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Introduction
Bone is the third most common site of metastasis after
lung and liver. About 10% of patients with metastatic
disease may sustain pathological fractures, and 65% of all
fractures requiring surgery occur in the femur.1
Pathological fractures are most distressing as severe pain
complicates the condition that may significantly affect the
patients' quality of life, leaving them with problems of
recumbence. Previously it was thought that these patients
had grave prognosis and 50% of them rarely survived
beyond three months.2 Recent advances and
multidisciplinary approach brought improvement in the
number of survivors. Successful management of the
patient requires recognition, diagnosis and treatment of
the underlying condition affecting the individual.3
Management of these pathological fractures and
impending fractures are quite different  from the others,
because of the associated disease and, if they remain
unrecognised, they can produce detrimental effects on
patients' life or limb.4
No clear guidelines or prospective studies exist regarding
treatment protocol for these lesions and the treatment is
based on the patient's symptoms and radiographic
appearance of the lesion. Fidler in 1973 assessed patients
with impending fractures with greater than 50% cortical
involvement and identified the improvement of pain
post-operatively after prophylactic internal fixation.5Mirel
proposed a scoring system for the prediction of fracture in
which several radiographic and clinical factors were
combined into a single score.6
In pathological fractures caused by metastatic bone
tumours, treatment is palliative rather than curative. The
majority of metastatic bone lesions are treated effectively
with non-surgical modalities such as radiation therapy,
chemotherapy, hormonal therapy and bisphosphonates.
Operative treatment may be required for patients with
existing or impending pathological fracture with
intractable pain that does not respond to any non-
operative procedure.7
The decision whether to perform prophylactic surgery
depends on several complex factors, including life
expectancy, functional demands of the patient,
compliance and ability to allow early mobilisation.8 Non-
surgical candidates are patients with limited life
expectancy, severe co-morbidities, small lesions,
radiosensitive tumours, or the general condition of the
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Abstract
Objective: To determine the survival rate and functional outcome of skeletal stabilisation in patients with
metastatic bone disease. 
Methods: The retrospective study was conducted at Aga Khan University Hospital, Karachi, and comprised data of
patients with non-spinal metastatic bone disease managed surgically from January 2002 to December 2010. All
patients had been managed by experienced orthopaedic, oncology and multidisciplinary teams. Patients managed
by non-oncologic orthopaedic surgeons were excluded. The prognostic influence of clinical, pathological and
treatment variables on Musculoskeletal Tumour Society score, range of motion, local complications and death rate
were measured. SPSS 19 was used for statistical analysis.
Results: Of the 49 patients whose records were included in the study, 21(42.9%) males and 28(57.1%) females with
an overall median age of 59 years. Most common primary tumour site was breast in 15(3.8%) followed by lungs in
11(22.4%), Open reduction and internal fixation was the mpst commonly used procedure in 18(36.7%) patients.
Mean duration of follow-up was 30.20±29.2 SD months (range: 10-48 months). The median patient survival was 23
months. 23% patients have superficial surgical site infection. Mean Musculoskeletal Tumour Society score was
23.73±14.3 SD. 
Conclusion: The results confirm the principle that surgery for metastatic disease is done primarily to improve
quality of life and ambulation status, and to alleviate pain. 
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patient being inadequate to tolerate anaesthesia and the
surgical procedure.
Advances in systematic treatment, multidisciplinary
approach, pain control and local modalities have changed
the philosophy towards aggressive care to provide
improvement in quality of remaining life. 
The current study was planned to determine the rate of
survival and functional outcome of skeletal stabilisation in
patients with metastatic bone disease.
Material and Methods
The retrospective study was conducted at Aga Khan
University Hospital (AKUH), Karachi, and comprised data
of patients with non-spinal metastatic bone disease
managed surgically from January 2002 to December
2010. All patients had been managed by experienced
orthopaedic, oncology and multidisciplinary teams.
Patients managed by non-oncologic orthopaedic
surgeons were excluded. The prognostic influence of
clinical, pathological and treatment variables on
Musculoskeletal Tumour Society (MSTS) score, range of
motion, local complications and death rate were
measured at 3-month follow-up. MSTS score is a validated
tool to assess the functional outcome which includes 6
categories, each given a numerical variable from 0-5. Pain,
function and emotional acceptance are used in the
evaluation of the upper and lower extremities. Use of
walking aids, gait and walking are evaluated for the lower
extremity, and hand positioning, dexterity and lifting
ability are evaluated for the upper extremity. The score
usually is expressed as its numerical value and can be
expressed as a percentage.9
Survival overtime was calculated using Kaplan-Meier
analysis. Starting from the date of the original surgery, the
patients were monitored either till patient's death or till
the date of last follow-up. SPSS 19 was used for statistical
analysis.
Results
Of the 107 available patient files, 23(21.5%) had to be
excluded for missing data and 32(29.9%) were lost to
follow-up. The final study sample, as such, stood at
49(45.8%) Of them, 21(42.9%) were males and 28(57.1%)
were females with an overall median age of 59 years
(range: 45-84 years). The peri-trochanteric region
showed the highest involvement in 16(32.7%) patients,
lower extremity in 10(20.4%) upper extremities in
10(20.4%), pelvis in 8(16.3%) and 5(10.2%) had
involvement of other regions.
The most common primary malignancy was breast,
affecting 15(31%) patients, followed by lungs in 11(23%),
unknown site 9(19%) prostrate 3(5%), renal cells 2(4%),
gastrointestinal (GI) tract 1(2%) and others affecting
8(16%).
Overall, 29(59%) lesions were found to be lytic on X-ray,
18(37%) mixed and 2(4%) blastic. Open reduction and
internal fixation (ORIF) was the most commonly
performed procedure in 18(37%) patients followed by
arthroplasty in 17(35%), intramedullary (IM) nailing in
10(20%) and Dynamic Hip Screw (DHS) in 4(8%)
individuals.
Mean MSTS score was 23.73±14.3 SD or 79.1% with the
worst score being 16. None of the patients had fixation
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Figure-1: Survival curve.
Figure-2:  Survival based on patient age.
failure whereas surgical site infection (SSI) was found in
10(20%) patients in whom it was managed with
antibiotics. No re-operations were required. 
Mean follow-up was 30.2±29.2 SD months (range 10-48
months). Median patient survival was 23 months. Survival
based on patient age was also calculated (Figures 1-2).
Median survival rate calculated using Kaplan-Meier
analysis was 75% at 1-year follow-up and 50% at 5-year
follow-up.
Discussion
Studying the outcome of surgical treatment of metastatic
bone disease is very difficult. These are severely affected
patients whose condition aggravates with the progressive
effects of the debilitating disease and the effects of the
treatment in the form of chemotherapy or radiotherapy
and other medical conditions. These factors may be
apparent with the attrition in the follow-up process. As
can be seen in our study, a number of patients did not
return for follow-up and the surgical results thus
remained unknown in our subgroup. The average MSTS
score in our study was 79.1% (or 23.7) which is very much
comparable with a study conducted in 2011 which
compared femoral metastasis.10
MIREL's score is very important for prophylactic fixation of
impending fracture and takes into account the site, size,
characteristics of the lesions and pain severity affecting
the patient's quality of life. Mirel's scoring system
suggested prophylactic fixation when a score was greater
than 86. The worst score in our sample was 16.
The limitation of our study was its retrospective nature
and the limited number of patients visiting a single
centre. We recommend the concept of having a tumour
registry at the national level which would possibly enable
standardised collection of data and inclusion of large
number of patients visiting various centres.
Conclusion
Our results confirm the principle that surgery for
metastatic disease is done primarily to improve quality of
life and ambulation status, and to alleviate pain. Mirel's
criterion was very useful in deciding when to operate. 
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